Fibrosis and structural remodeling of the lung tissue can significantly impair lung function,
often with fatal consequences. The etiology of pulmonary fibrosis (PF) is diverse and …

Idiopathic pulmonary fibrosis (IPF) is a long-lasting, continuously advancing, and irrevocable
interstitial lung disorder with an obscure origin and inadequately comprehended …

Fibrosis is a process of tissue repair that results in the slow creation of scar tissue to replace
healthy tissue and can affect any tissue or organ. Its primary feature is the massive …

The objective of this study was to assess whether mesenchymal stem cells (MSCs) therapy
could offer survival advantages for patients with novel coronavirus disease 2019 (COVID …

Fibrosis has been characterized as a global health problem and ranks as one of the primary
causes of organ dysfunction. Currently, there is no cure for pulmonary fibrosis, and limited …

Advances in stem cell technology offer new possibilities for patients with untreated diseases
and disorders. Stem cell-based therapy, which includes multipotent mesenchymal stem cells …

Idiopathic pulmonary fibrosis (IPF) is a lethal and chronic lung disease that occurs due to
persistent epithelial cell injury and abnormal extracellular matrix (ECM) deposition …

Reactivation and infection with cytomegalovirus (CMV) are frequently observed in recipients
of solid organ transplants, bone marrow transplants, and individuals with HIV infection. This …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive respiratory disease. Arguably,
the complex interplay between immune cell subsets, coupled with an incomplete …

Pulmonary fibrosis (PF) is a complex disorder with high morbidity and mortality. Limited
efficacies of the available drugs drive researchers to seek for new therapies. Saroglitazar …